Treatment of endometriosis with the GnRH agonist nafarelin acetate
- PMID: 1672673
Treatment of endometriosis with the GnRH agonist nafarelin acetate
Abstract
Additional details of a multicenter study of nafarelin acetate with particular attention to a unique endometriosis scoring system utilized are reviewed. Additional information regarding the relapse of symptoms of 10 patients treated with nafarelin and danazol during a 6- to 12-month follow-up interval is described. Transient decreases in leukocytes previously reported by other investigators were observed in 3 of 8 patients, but appear to represent a laboratory artifact.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical